Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Unknown 15Not yet recruiting 5Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

pembrolizumab 196Nivolumab 145Carboplatin 134Specimen Handling 130Magnetic Resonance Spectroscopy 115Cyclophosphamide 109Paclitaxel 106Cisplatin 98Biopsy 97Radiotherapy 90durvalumab 81Dexamethasone 79atezolizumab 73Ipilimumab 62Gemcitabine 62Rituximab 59Doxorubicin 59Lenalidomide 55Docetaxel 55olaparib 53Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 47Oxaliplatin 47Radiosurgery 43venetoclax 42Prednisone 42Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × aumolertinib × Clear all
NCT06300424 2026-04-29

NEOVADE

Guangdong Provincial People's Hospital

Phase 2 Active not recruiting
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04685070 2024-08-14

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Active not recruiting
56 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡